Last reviewed 2026-04-23 · How we verify

Orelabrutinib + R-CHOP

Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, and R-CHOP is a chemotherapy regimen that includes rituximab, cyclophosphamide, doxorubicin, and prednisone.

Orelabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor, and R-CHOP is a chemotherapy regimen that includes rituximab, cyclophosphamide, doxorubicin, and prednisone. Used for Treatment of relapsed or refractory mantle cell lymphoma.

At a glance

Mechanism of action

Orelabrutinib works by selectively inhibiting the BTK enzyme, which is involved in the activation of B cells. R-CHOP is a combination of chemotherapy drugs that target rapidly dividing cancer cells. The combination of orelabrutinib and R-CHOP is used to treat certain types of non-Hodgkin lymphoma.

Approved indications

• Treatment of relapsed or refractory mantle cell lymphoma

Common side effects

• Neutropenia
• Anemia
• Thrombocytopenia
• Fatigue
• Nausea

Key clinical trials

• Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. (PHASE2)
• Methotrexate or Thiotepa Combined With R-CHOP and Orelabrutinib in CNSL Patients (PHASE2)
• CR-CHOP+X in Previously Untreated DEL (PHASE2)
• Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） (PHASE2)
• Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI (PHASE2)
• A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (PHASE3)
• An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
• A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.